

SAMPLE

Allogeneic CAR

Patent Landscape Analysis

September 2023

TABLE OF CONTENTS

INTRODUCTION	5	PATENT SEGMENTATION	45
<ul style="list-style-type: none">- CAR therapy- Scope of the report- Reading guide- Main patent assignees		<ul style="list-style-type: none">- Definition- Main assignees by technology- Cells- Cells origin- Gene editing tool- Therapeutic area	
EXECUTIVE SUMMARY	11	IP PROFILE OF KEY PLAYERS	62
PATENT LANDSCAPE OVERVIEW	17	Overview, key patents & clinical trials of:	
<ul style="list-style-type: none">- Time evolution of patent publications- Ranking of most prolific patent applicants- Patenting activity of IP leading companies- Mapping of main current IP holders- Time evolution of main patent assignees		<ul style="list-style-type: none">- Adicet Bio- Allogene Therapeutics- Collectis- CRISPR Therapeutics- Fate Therapeutics- Gracell- Precision Biosciences	
NEWCOMERS	24	METHODOLOGY	111
<ul style="list-style-type: none">- Startup companies- Established companies		<ul style="list-style-type: none">- Patent search, selection and analysis- Search strategy- Terminologies for patent analysis- Strength and blocking potential	
COLLABORATIONS	32	KNOWMADE PRESENTATION	119
IP POSITION OF MAIN APPLICANTS	36	CONTACT	122
<ul style="list-style-type: none">- IP leadership of patent applicants- IP prior art blocking potential of patent applicants- Key patents- Strength index of patent portfolios			
MAIN EP PATENT OPPOSITIONS	43		

THE AUTHORS



Dr. Fabienne Massa

Fabienne works for Knowmade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular and Cellular Biology from the IPMC (Sophia Antipolis, France). She also holds a Master of Business Management from IAE (Nice, France) and she previously worked in the pharmaceutical industry.

Contact: fabienne.massa@knowmade.fr



Dr. Brice Sagot

CTO and co-founder of KnowMade. He leads the Biotechnology and Life Sciences department. He holds a PhD in Molecular Biology from the University of Nice Sophia-Antipolis (France).

Contact: brice.sagot@knowmade.fr

Specialized in analysis of patents and scientific information, Knowmade provides Technology Intelligence and IP strategy consulting services. The company is supporting R&D organizations, industrial companies and investors in their business development by offering them a deep understanding of the technology trends and their IP environment. Knowmade operates in the following industrial sectors: Microelectronics, Compound Semiconductors, Power Electronics, RF & Microwave Devices, MEMS Sensors & Actuators, LED/OLED, Imaging & Display, Photonics, Battery, Manufacturing & Advanced Packaging, Micro & Nanotechnology, Biotechnology, Cellular & Molecular Biology, Microbiology, Dermatology, Pharmacology, Oncology, Immunology, Medical Devices & Medical Imaging, Agri-Food & Environment. Knowmade performs prior art search, patent landscape analysis, scientific literature analysis, patent valuation and freedom-to-operate analysis. In parallel, the company proposes litigation/licensing support, technology scouting and IP watch service. Knowmade's analysts combine their technical and patent expertise by using powerful analytics tools and proprietary methodologies to deliver relevant patent analyses and scientific reviews.

We Know Technology, We Know Patents

INTRODUCTION

Scope of the report

- This report provides a detailed picture of the patent landscape for **CAR allogeneic**.
- This report covers **patents published worldwide up to March 2023**.
- We have selected and analyzed about **+410 patent families** relevant to the scope of this report.

You want a deeper analysis on technologies or companies

Contact us for a custom report



Included in the report

- ✓ All immune cells: T cells, NK, macrophages, etc.
- ✓ Immune cells derived from PBMC (peripheral blood of donor), iPSC, cord blood or placenta.
- ✓ All gene editing tools to engineer CAR immune cells: CRISPR, TALEN, Meganuclease, etc.
- ✓ All CAR constructs: various binding domains, hinge, transmembrane and intracellular domains, and various “armor” proteins expression (cytokine, antibody, etc.).
- ✓ All therapeutics applications.

Not included in the report

- X Autologous CAR
- X Patent applications not clearly focused on allogeneic CAR technology

INTRODUCTION

Key features of the report

- **Excel database** comprising all analyzed patents of the report is provided.
- This **patent database** allows multi-criteria searches, including:
 - Patent publication number
 - Hyperlinks to the original documents
 - Priority date
 - Title
 - Abstract
 - Patent assignees
 - Technical segmentation
 - Legal status for each member of the patent family.
- The findings, interpretations and conclusions expressed in this report are entirely those of Knowmade and may not constitute or imply endorsement by a decision-making body such as a court of law or a patent office. Any assessment of the effect or scope of pending applications or granted patents reflects our own views and these are not necessarily those of a Patent Attorney. Should confirmation of our assessment in this respect be required, we recommend that you seek the advice of a national Patent Attorney.




Patent Landscape Overview

Patent assignees, IP dynamics, patent legal status, patent geographical coverage


PATENT LANDSCAPE OVERVIEW

Time Evolution of Patent Publications



PATENT LANDSCAPE OVERVIEW

Mapping of Main Current Patent Holders



PATENT LANDSCAPE OVERVIEW

Time Evolution of Main Patent Assignees


Assignee*	Nb of patent families	Average age of the patent portfolio	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023		
ALLOGENE THERAPEUTICS	4	9				1					1			1	1				1	1		
UNIVERSITY OF TEXAS	3	6												1	1							
ALLOGENE THERAPEUTICS	2	6																				
ALLOGENE THERAPEUTICS	46	5									1	2	11	5	1	6	8	1	3	6	2	
ALLOGENE THERAPEUTICS	17	4												4	3	3	4	3				
ALLOGENE THERAPEUTICS	7	4												1	1	1	3	1				
ALLOGENE THERAPEUTICS	18	3											1	1	1	1	2	1	4	4	2	
ALLOGENE THERAPEUTICS	18	3												2	1	1	6	3	1	1	5	
ALLOGENE THERAPEUTICS	12	3															5	3	3	1	1	
ALLOGENE THERAPEUTICS	6	3													1		3		2			
ALLOGENE THERAPEUTICS	34	2														1	3	5	11	12	2	
ALLOGENE THERAPEUTICS	20	2														1	1	3	2	6	5	2
ALLOGENE THERAPEUTICS	8	2																				
ALLOGENE THERAPEUTICS	7	2																				
ALLOGENE THERAPEUTICS	6	2																				
ALLOGENE THERAPEUTICS	6	2																				
ALLOGENE THERAPEUTICS	6	2																				
ALLOGENE THERAPEUTICS	8	1																				
ALLOGENE THERAPEUTICS	7	1																				
ALLOGENE THERAPEUTICS	6	1																				
ALLOGENE THERAPEUTICS	4	1																				
ALLOGENE THERAPEUTICS	3	1																				
ALLOGENE THERAPEUTICS	3	1																				
ALLOGENE THERAPEUTICS	2	1																				
ALLOGENE THERAPEUTICS	2	1																				
ALLOGENE THERAPEUTICS	2	1																				
ALLOGENE THERAPEUTICS	2	0																				
ALLOGENE THERAPEUTICS	2	0																				
ALLOGENE THERAPEUTICS	2	0																				

* Assignees are selected based on the number of patent families and on the average age of the patent portfolio (historical player, newcomer, etc.).

This table shows the changes in the number of patent families published by the main players, between 2006 and 2023. American academics, such as the City of Hope and the Memorial Sloan Kettering Cancer center, were pioneering players in allogeneic CAR T cells. In 2013, **Collectis** was the 1st company to develop allogeneic CAR technology. To make it happens, many investments were necessary. First, in 2010, Collectis acquired all assets of CytoPulse (transfection by electroporation). Then, in 2011, TAL nucleases patents were exclusively licensed to Collectis by the University of Minnesota. Analysis of patent filing dates has revealed some new players in the field, which will be discussed in the following slides.

- The acceleration in allogeneic (Axicabtagene Ciloleuce) for
- The recent growth in patent Therapeutics, or Allogene Th

Ranking of patent assignees according to the number of their patent families



Allogeneic CAR – Patent Landscape Analysis - Ref.: KM23003 © 2023 All rights reserved | www.knowmade.com 19

Allogeneic CAR – Patent Landscape Analysis - Ref.: KM23003 © 2023 All rights reserved | www.knowmade.com 23

Patent Landscape Overview

Identify main EP oppositions, collaborations and newcomers

SAMPLE

MAIN EP PATENT OPPOSITIONS

Main oppositions on EP patents

This table shows **main oppositions filed against European patents**. For each opposed patent, application date, assignee, opponent, opposition year and results are presented. These opposition procedures suggest that these patents may impede competitors' ability to develop their products. If upheld, these patents could enhance the players' IP positions and may require competitors to take out licenses or find alternative solutions. Given the growing interest in the field and the 239 pending patents in Europe, the number of opposition proceedings is expected to rise in the future.

Assignee	Opposed Patent	Application filing date	Opponent	Opposition	Title	Result
[Redacted]	[Redacted]	2018-08-08	[Redacted]	[Redacted]	[Redacted]	[Redacted]
	[Redacted]	2018-08-08	[Redacted]	[Redacted]	[Redacted]	[Redacted]
	[Redacted]	2018-08-08	[Redacted]	[Redacted]	[Redacted]	[Redacted]
	[Redacted]	2018-08-08	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	2014-04-02	[Redacted]	[Redacted]	[Redacted]	
[Redacted]	[Redacted]	2014-08-14	[Redacted]	[Redacted]	[Redacted]	
[Redacted]	[Redacted]	2013-09-04	[Redacted]	[Redacted]	[Redacted]	

* Companies acting as a front for other parties to conceal their identities (straw man).



IP COLLABORATIONS

Main IP collaborations (1/2)

Co-assignees	Organization type	Representative members of patent families	Link	Earliest publication years	Title	Patent families' topic
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]
[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]	[Redacted]



IP NEWCOMERS

Startup companies (2/4)

Assignee	Company information	Company size	Patent family	Main relevant selected patent
	Founded in 2021, Appia Bio is focused on discovering and developing engineered microbial cell strains with a broad array of industrial, food, and other uses. Our platform focuses on developing strains of bacteria for the production of high-value products.	~10	2	EP3848482A1 (2021.09.01) - 2022.03.02 The present invention relates to a method for producing a cell with enhanced properties. The cell is produced by introducing a DNA construct into a host cell. The DNA construct encodes a protein that is expressed in the host cell. The protein is then purified from the host cell.
	Artiva, an American company founded in 2020, is focused on developing a platform of off-the-shelf, modular cell strains for the production of high-value products. Our platform focuses on developing strains of bacteria for the production of high-value products.	~100	4	US20220000000A1 (2022.01.01) - 2022.01.01 The present invention relates to a method for producing a cell with enhanced properties. The cell is produced by introducing a DNA construct into a host cell. The DNA construct encodes a protein that is expressed in the host cell. The protein is then purified from the host cell.
	Beam Therapeutics, founded in 2014, uses a platform of off-the-shelf, modular cell strains for the production of high-value products. Our platform focuses on developing strains of bacteria for the production of high-value products.	~1000	5	US20220000000A1 (2022.01.01) - 2022.01.01 The present invention relates to a method for producing a cell with enhanced properties. The cell is produced by introducing a DNA construct into a host cell. The DNA construct encodes a protein that is expressed in the host cell. The protein is then purified from the host cell.




Patent Portfolios Benchmarking: Beyond the Quantity

Who has the best patent portfolio?

SAMPLE

IP POSITION OF PATENT APPLICANTS


IP Leadership of Patent Assignees



Cellgene shows a strong IP leadership in the field of cell-based CAR, with 281 granted patents and 212 pending patent applications, thus forming a portfolio and creating geographical coverage. Although Cellgene is a general biotech area, subsequent families published as early as 2014. It has remained in the case ever since. The company is known for its gene editing technology (CRISPR).
 Genentech Therapeutics was also considered as a research institution.

IP POSITION OF PATENT APPLICANTS


Prior Art Blocking Potential



Patent portfolios with a high prior art IP blocking potential are relevant in evaluating the patentability of patent applications filed afterwards. Old patent families are more likely to receive a high number of citations from subsequent applications. Therefore, well-cited patent families are likely to be relevant prior art "blocking" the patenting activity of competitors (i.e., novelty and inventiveness assessment).

IP POSITION OF PATENT APPLICANTS

Strength Index (2/2)



Cellgene has the strongest strength index due to its high number of patent families, granted patents, and pending patent applications, as well as extensive forward citations and extensive geographical coverage. Genentech Therapeutics is known for its gene editing technology (CRISPR).

The University of Texas has a medium strength index because it owns few granted patents (compared to Cellgene). However, it has a high number of pending applications with a large geographical coverage. However, it has a highly diversified portfolio which is mostly focused on the use of engineered cell cells, rather than on a specific technology.

Genentech Therapeutics, Genentech Therapeutics, Genentech Therapeutics and Genentech Therapeutics also have a medium strength index despite the fact of citations from their patent portfolios are generally cited probably because they focus on a specific technology (CRISPR) for each of their drug therapies, although Genentech Therapeutics and Genentech Therapeutics have shared the same patent, i.e., a high number of pending applications and a broad geographical coverage. Regarding Genentech Therapeutics, it owns a large number of patents in pending applications.

Genentech Therapeutics is a company founded in 2011, has received few forward citations despite a moderate number of pending applications and a wide geographical coverage.

IP profile of key players

IP portfolio summary, IP strategy, key patents and clinical trials

SAMPLE

A focus on the 7 main players is provided in a dedicated section. For each player, the **allogeneic CAR patent portfolio** is statistically analyzed to provide an overview of its strengths and level of IP activity. The key patents of the player is then reviewed with its clinical trials.



IP PROFILE OF KEY PLAYERS

Allogene Therapeutics: key patent family (1/4)

The table below summarizes all patent families identified in the report for Allogene Therapeutics, including patent number, 1st application date, legal status, invention subject, cell used, CAR target, cell origin, gene editing method and target, and pathology.

Patent no & 1 st appl. date	Object of invention	Cell	Target	Cells origin	Gene editing method	Gene editing target	Pathology	Complementary information
WO/2019/126118* 2019-02-25 Granted (JP, MA, BY)	Polypeptide encoding a CAR	T+H	CD123 or SEMA	Peripheral blood	/	/	Hematological cancer	CAR comprises a mAb-specific epitope. This epitope can be bound by an epitope-specific cell for in vitro cell sorting and/or in vivo cell depletion of T cells expressing a CAR comprising such epitope. CAR expresses anti-CD123 (pV with CD3) minicore.
WO/2019/126027* 2019-02-25 Dead	Structure of a CAR	T+H	HSP70	Peripheral blood	TALEN	8D TCR (TRAC gene)	Hematological cancer	CAR with extracellular domain comprises one epitope binding epitope with an CD30 minicore. The CAR is a single chain CAR (scCAR).
WO/2019/126028* 2019-02-25 Granted (JP, MA, BY)	Structure of a CAR	T+H	CD123	Peripheral blood	TALEN	8D TCR (TRAC gene)	Hematological cancer	CAR with extracellular domain comprises one epitope binding epitope with an CD30 minicore. The CAR is a single chain CAR (scCAR).
WO/2019/126029* 2019-02-25 Dead	Structure of a CAR	T+H	CD123	Peripheral blood	TALEN			
WO/2019/126030* 2019-02-25 Dead	Structure of a CAR	T+H	CD123	Peripheral blood	TALEN			

IP PROFILE OF KEY PLAYERS

Adicet Bio: overview

Adicet Bio, an American company founded in 2014, identifies allogeneic gene edited T and NK cells, a novel type of cell therapy. These cells combine adaptive (A) T (Klebsiella) and innate (NK) cell immunity to specifically recognize and eliminate tumor cells while sparing normal healthy cells. To date, the use of these cells has been demonstrated in 11 clinical trials. Adicet Bio has developed a proprietary anti-tumor gene editing and insertional therapy targeting CD30 for the potential treatment of relapsed or refractory CD30+ hematological lymphomas. Adicet Bio's gene editing tool is a novel gene editing tool, but is not unique in the coding space. Instead, 80% of its 100 patents are pending applications. The company has a strong portfolio of therapies with pending applications in US, Europe and Asia.

* These patents applications belong to the same patent family. This patent family comprises several

KnowMade

IP PROFILE OF KEY PLAYERS

Cellectis: main clinical trials (1/2)


A summary of the clinical trials related to Cellectis available on ClinicalTrials.gov as of May 14, 2023. The table below summarizes all clinical trials related to Cellectis, including trial number, study title, condition, intervention, and status.

Trial No.	Related patent	Study title	Condition	Intervention	Status
NCT04687429	WO/2019/126029	Study Evaluating UCART2022 in B-Cell Non-Hodgkin Lymphoma	B-cell Non-Hodgkin Lymphoma	Biological: UCART2022	Recruiting
NCT04186807	WO/2019/126027	Phase 1/2 Study of UCART12 in Patients With Relapsed or Refractory CD20+ B-cell Acute Lymphoblastic Leukemia (B-ALL)	B-cell Acute Lymphoblastic Leukemia	Biological: UCART12	Recruiting
NCT04143019	WO/2019/126028	Study Evaluating Safety and Efficacy of UCART (Targeting CD30) in Patients With Relapsed/Refractory Multiple Myeloma (RMM)	Relapsed/Refractory Multiple Myeloma	Biological: UCART30	Recruiting

KnowMade



Allogene



Adicet Bio: overview

Allogeneic CAR - Patent Landscape Analysis - Ref.: KM23003

© 2023 All rights reserved | www.knowmade.com

Excel file with all patents analyzed in the report

Useful patent database allows multi-criteria searches

SAMPLE

General information										Cellr			Cellr origin			Gene editing tool					Therapy		
Family name	Patent number	Patent assignee	Title	Abstract	Earliest publication date	Citing patents (Forward citations)	PDF file	Bibliography	T cells	NK	Other	Peripheral blood	iPSC	Card blood & placenta	CRISPR	TALEN	ZFN	Other	Megacytase	Hematological malignancy	Solid tumor		
10029402	WO2022115472	A2 BIOTHERAPEUTICS	(WO2022115472) Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity	(WO2022115472) The disclosure relates to immune cells comprising systems of two engineered receptors each having a ligand binding domain, cells actively designed to target cells identified by loss of heterozygosity and used to treat a disease or disorder, for example, cancer. The disclosure provides immune cells expressing two engineered receptors, methods of making same, and polynucleotides and vectors encoding same.	2022-06-02		Open	Open	X						X						X	X	
94629471	JP202304185 US2023009275 CN115347976 EP4072567 KR10-2022-0123452 IL243459 AU2020399423 BR112022010669 WO2022115358 CA3160609	ADICET BIO	(EP4072567) Methods for expanding gamma delta T cell populations with multivalent agents and compositions thereof	(EP4072567) The present invention relates to methods comprising reliable multivalent activating agents for the selective in vitro and in vivo activation and expansion of T cell population(s), including specific T cell subpopulation(s) of interest and admixtures thereof, and methods for using the same for therapeutic purposes. Methods and compositions of the disclosure are useful in the treatment of various cancer, infectious diseases, and immune disorders.	2021-06-10		Open	Open	X			X									X	X	
99202920	WO2022115358 JP2022510387 US20220219747 JP2022510387 BR112021010804 CN11518624 EP3340757 KR10-2021-009415 MX2021006503 IL233614 SG112021058600 AU2019394877 JP2022510704 JP2022510704 US20210388100 EP3360645	ADICET BIO	(EP3340757) Methods for expanding gamma delta T cell populations with multivalent agents and compositions thereof	(EP3340757) The present invention relates to methods comprising reliable multivalent activating agents for the selective in vitro and in vivo activation and expansion of T cell population(s), including specific T cell subpopulation(s) of interest and admixtures thereof, and methods for using the same for therapeutic purposes. Methods and compositions of the disclosure are useful in the treatment of various cancer, infectious diseases, and immune disorders.	2020-06-11	WO2022109477	Open	Open	X												X	X	
9319324	BR112021006152 CN11056232 EA20219926 KR10-2021-0070320 IL231922 MX2021003745 AU2019354291 JP2022513221 US20210388109 CN115272016 EA202199415 EP3360716 BR112021006254 KR10-2021-0087458 MX2021003744 IL231943 AU2019354295 JP2021502216 CN11610349 EP3710472 MX2020005005 KR10-2020-0098518 IL214640 SG112021004506W AU2018370120 CA2082818 WO2019099744 IL301527 KR10-2519661	ADICET BIO	(EP3360645) Comparisons and methods regarding engineered and non-engineered gamma delta T cells for treatment of hematological tumor	(EP3360645) Aspects of the invention include comparisons and methods for treatment of hematological tumors with engineered or non-engineered $\gamma\delta$ T cells. In some embodiments, the $\gamma\delta$ T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD30 binding domain or anti-B cell maturation antigen (BCMA) binding domain, a CD80 hinge and transmembrane domain, a cartilaginous domain, a CD27 signaling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as zeta IL15 domain.	2020-04-09	US20210249673; US11207249 CN11667640; CN113667640B	Open	Open	X			X										X	
9319330	BR112021006254 KR10-2021-0087458 MX2021003744 IL231943 AU2019354295 JP2021502216 CN11610349 EP3710472 MX2020005005 KR10-2020-0098518 IL214640 SG112021004506W AU2018370120 CA2082818 WO2019099744 IL301527 KR10-2519661	ADICET BIO	(EP3360716) Comparisons and methods regarding engineered and non-engineered gamma delta T cells for treatment of solid tumor	(EP3360716) Aspects of the invention include comparisons and methods for treatment of solid tumors with engineered or non-engineered $\gamma\delta$ T cells. In some embodiments, the $\gamma\delta$ T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-TR2 binding domain, a CD80 hinge and transmembrane domain, a cartilaginous domain, a CD27 signaling domain, a combination thereof, or all thereof. The CAR construct can contain an anti-GPC3 binding domain, a CD80 hinge and transmembrane domain, a cartilaginous domain, a CD27 signaling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as zeta IL15 domain.	2020-04-09	US20210069248; US11058725	Open	Open	X			X										X	
84600013	BR112021006254 KR10-2021-0087458 MX2021003744 IL231943 AU2019354295 JP2021502216 CN11610349 EP3710472 MX2020005005 KR10-2020-0098518 IL214640 SG112021004506W AU2018370120 CA2082818 WO2019099744 IL301527 KR10-2519661	ADICET BIO	(EP3710472) Methods for selective expansion of delta 2 gamma delta T cell populations and compositions thereof	(EP3710472) The present application is directed to agents that bind an epitope specific to $\delta 2\gamma\delta$ TCR. Such agents can be, but are not limited to, an antibody or fragment thereof. Also described herein are methods for using the agents, e.g., to expand and/or selectively expand $\delta 2\gamma\delta$ T cells. Also described herein are methods of using expanded $\delta 2\gamma\delta$ T cells for treatment of a subject in need thereof.	2019-05-23	WO2020220016 CN11748519 WO202236024	Open	Open	X			X										X	

Patent information

Segmentation

ORDER FORM

Allogeneic CAR

Patent Landscape Analysis – September 2023

Ref.:KM23003



SHIP TO

Name (Mr/Ms/Dr/Pr):

Job Title:

Company:

Address:

City:

State:

Postcode/Zip:

Country:

VAT ID Number for EU members:

Tel:

Email:

Date:

PAYMENT METHODS

Check

To pay your invoice using a check, please mail your check to the following address:

KnowMade S.A.R.L.
2405 route des Dolines
06902 Valbonne Sophia Antipolis
FRANCE

Money Transfer

To pay your invoice using a bank money wire transfer please contact your bank to complete this process. Here is the information that you will need to submit the payment:

Payee: KnowMade S.A.R.L.
Bank: Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France
IBAN: FR76 1460 7003 6360 6214 5695 139
BIC/SWIFT: CCBPFRPPMAR

Paypal

In order to pay your invoice via PAYPAL, you must first register at www.paypal.com. Then you can send money to the KnowMade S.A.R.L. by entering our E-mail address contact@knowmade.fr as the recipient and entering the invoice amount.

RETURN ORDER BY

E-mail: contact@knowmade.fr

Mail: KnowMade S.A.R.L., 2405 route des Dolines, 06902 Valbonne Sophia Antipolis, FRANCE

PRODUCT ORDER

€4,990 – Multi user license*

For price in dollars, please use the day's exchange rate. For French customer, add 20% for VAT.

All reports are delivered electronically in PDF format at payment reception.

**The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded. Please be aware that the report is watermarked on each page, with the name of the recipient and the organization (the name mentioned on the PO). This watermark also reaffirms that report sharing is not allowed.*

I hereby accept Knowmade's Terms and Conditions of Sale

Signature:

Terms and Conditions of Sales

DEFINITIONS

“Acceptance”: Action by which the Buyer accepts the terms and conditions of sale in their entirety. It is done by signing the purchase order which mentions “I hereby accept Knowmade’s Terms and Conditions of Sale”.

“Buyer”: Any business user (i.e. any person acting in the course of its business activities, for its business needs) entering into the following general conditions to the exclusion of consumers acting in their personal interests.

“Contracting Parties” or “Parties”: The Seller on the one hand and the Buyer on the other hand.

“Intellectual Property Rights” (“IPR”) means any rights held by the Seller in its Products, including any patents, trademarks, registered models, designs, copyrights, inventions, commercial secrets and know-how, technical information, company or trading names and any other intellectual property rights or similar in any part of the world, notwithstanding the fact that they have been registered or not and including any pending registration of one of the above mentioned rights.

“License”: For the reports and databases, 2 different licenses are proposed. The buyer has to choose one license:

1. Single user license: a single individual at the company can use the report.

2. Multi user license: The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded.

“Products”: Reports are established in PowerPoint and delivered on a PDF format and the database may include Excel files.

“Seller”: Based in Sophia Antipolis (France headquarters), Knowmade is a technology intelligence company specialized in the research and analysis of scientific and technical information. We provide patent landscapes and scientific state of the art with high added value to businesses and research laboratories. Our intelligence digests play a key role to define your innovation and development strategy.

1. SCOPE

1.1 The Contracting Parties undertake to observe the following general conditions when agreed by the Buyer and the Seller. ANY ADDITIONAL, DIFFERENT, OR CONFLICTING TERMS AND CONDITIONS IN ANY OTHER DOCUMENTS ISSUED BY THE BUYER AT ANY TIME ARE HEREBY OBJECTED TO BY THE SELLER, SHALL BE WHOLLY INAPPLICABLE TO ANY SALE MADE HEREUNDER AND SHALL NOT BE BINDING IN ANY WAY ON THE SELLER.

1.2 This agreement becomes valid and enforceable between the Contracting Parties after clear and non-equivocal consent by any duly authorized person representing the Buyer. For these purposes, the Buyer accepts these conditions of sales when signing the purchase order which mentions “I hereby accept Knowmade’s Terms and Conditions of Sale”. This results in acceptance by the Buyer.

1.3 Orders are deemed to be accepted only upon written acceptance and confirmation by the Seller, within [7 days] from the date of order, to be sent either by email or to the Buyer’s address. In the absence of any confirmation in writing, orders shall be deemed to have been accepted.

2. MAILING OF THE PRODUCTS

2.1 Products are sent by email to the Buyer:

- within [1] month from the order for Products already released; or

- within a reasonable time for Products ordered prior to their effective release. In this case, the Seller shall use its best endeavours to inform the Buyer of an indicative release date and the evolution of the work in progress.

2.2 Some weeks prior to the release date the Seller can propose a pre-release discount to the Buyer.

The Seller shall by no means be responsible for any delay in respect of article 2.2 above, and including in cases where a new event or access to new contradictory information would require for the analyst extra time to compute or compare the data in order to enable the Seller to deliver a high quality Products.

2.3 The mailing of the Product will occur only upon payment by the Buyer, in accordance with the conditions contained in article 3.

2.4 The mailing is operated through electronic means either by email via the sales department. If the Product’s electronic delivery format is defective, the Seller undertakes to replace it at no charge to the Buyer provided that it is informed of the defective formatting within 90 days from the date of the original download or receipt of the Product.

2.5 The person receiving the Products on behalf of the Buyer shall immediately verify the quality of the Products and their conformity to the order. Any claim for apparent defects or for non-conformity shall be

sent in writing to the Seller within 8 days of receipt of the Products. For this purpose, the Buyer agrees to produce sufficient evidence of such defects.

2.6 No return of Products shall be accepted without prior information to the Seller, even in case of delayed delivery. Any Product returned to the Seller without providing prior information to the Seller as required under article 2.5 shall remain at the Buyer’s risk.

3. PRICE, INVOICING AND PAYMENT

3.1 Prices are given in the orders corresponding to each Product sold on a unit basis or corresponding to annual subscriptions. They are expressed to be inclusive of all taxes. The prices may be reevaluated from time to time. The effective price is deemed to be the one applicable at the time of the order.

3.2 Payments due by the Buyer shall be sent by cheque payable to Knowmade, PayPal or by electronic transfer to the following account:

Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France

BIC or SWIFT code: CCBPFRPPMAR

IBAN: : FR76 1460 7003 6360 6214 5695 139

To ensure the payments, the Seller reserves the right to request down payments from the Buyer. In this case, the need of down payments will be mentioned on the order.

3.3 Payment is due by the Buyer to the Seller within 30 days from invoice date, except in the case of a particular written agreement. If the Buyer fails to pay within this time and fails to contact the Seller, the latter shall be entitled to invoice interest in arrears based on the annual rate Refi of the «BCE» + 7 points, in accordance with article L. 441-6 of the French Commercial Code. Our publications (report, database, tool...) are delivered only after reception of the payment.

3.4 In the event of termination of the contract, or of misconduct, during the contract, the Seller will have the right to invoice at the stage in progress, and to take legal action for damages.

4. LIABILITIES

4.1 The Buyer or any other individual or legal person acting on its behalf, being a business user buying the Products for its business activities, shall be solely responsible for choosing the Products and for the use and interpretations he makes of the documents it purchases, of the results he obtains, and of the advice and acts it deduces thereof.

4.2 The Seller shall only be liable for (i) direct and (ii) foreseeable pecuniary loss, caused by the Products or arising from a material breach of this agreement

4.3 In no event shall the Seller be liable for:

a) damages of any kind, including without limitation, incidental or consequential damages (including, but not limited to, damages for loss of profits, business interruption and loss of programs or information) arising out of the use of or inability to use the Seller’s website or the Products, or any information provided on the website, or in the Products;

b) any claim attributable to errors, omissions or other inaccuracies in the Product or interpretations thereof.

4.4 All the information contained in the Products has been obtained from sources believed to be reliable. The Seller does not warrant the accuracy, completeness adequacy or reliability of such information, which cannot be guaranteed to be free from errors.

4.5 All the Products that the Seller sells may, upon prior notice to the Buyer from time to time be modified by or substituted with similar Products meeting the needs of the Buyer. This modification shall not lead to the liability of the Seller, provided that the Seller ensures the substituted Product is similar to the Product initially ordered.

4.6 In the case where, after inspection, it is acknowledged that the Products contain defects, the Seller undertakes to replace the defective products as far as the supplies allow and without indemnities or compensation of any kind for labor costs, delays, loss caused or any other reason. The replacement is guaranteed for a maximum of two months starting from the delivery date. Any replacement is excluded for any event as set out in article 5 below.

4.7 The deadlines that the Seller is asked to state for the mailing of the Products are given for information only and are not guaranteed. If such deadlines are not met, it shall not lead to any damages or cancellation of the orders, except for non-acceptable delays exceeding [4] months from the stated deadline, without information from the Seller. In such case only, the Buyer shall be entitled to ask for a reimbursement of its first down payment to the exclusion of any further damages.

4.8 The Seller does not make any warranties, express or implied, including, without limitation, those of

saleability and fitness for a particular purpose, with respect to the Products. Although the Seller shall take reasonable steps to screen Products for infection of viruses, worms, Trojan horses or other codes containing contaminating or destructive properties before making the Products available, the Seller cannot guarantee that any Product will be free from infection.

5. FORCE MAJEURE

The Seller shall not be liable for any delay in performance directly or indirectly caused by or resulting from acts of nature, fire, flood, accident, riot, war, government intervention, embargoes, strikes, labor difficulties, equipment failure, late deliveries by suppliers or other difficulties which are beyond the control, and not the fault of the Seller.

6. PROTECTION OF THE SELLER’S intellectual property

6.1 All intellectual property rights attached to the Products are and remain the property of the Seller and are protected under French and international copyright law and conventions.

6.2 The Buyer agreed not to disclose, copy, reproduce, redistribute, resell or publish the Product, or any part of it to any other party other than employees of its company. The Buyer shall have the right to use the Products solely for its own internal information purposes. In particular, the Buyer shall therefore not use the Product for purposes such as:

- Information storage and retrieval systems;

- Recordings and re-transmittals over any network (including any local area network);

- use in any timesharing, service bureau, bulletin board or similar arrangement or public display;

- Posting any Product to any other online service (including bulletin boards or the Internet);

- Licensing, leasing, selling, offering for sale or assigning the Product.

6.3 The Buyer shall be solely responsible towards the Seller of all infringements of this obligation, whether this infringement comes from its employees or any person to whom the Buyer has sent the Products and shall personally take care of any related proceedings, and the Buyer shall bear related financial consequences in their entirety.

6.4 The Buyer shall define within its company point of contact for the needs of the contract. This person will be the recipient of each new report in PDF format. This person shall also be responsible for respect of the copyrights and will guaranty that the Products are not disseminated out of the company.

7. TERMINATION

7.1 If the Buyer cancels the order in whole or in part or postpones the date of mailing, the Buyer shall indemnify the Seller for the entire costs that have been incurred as at the date of notification by the Buyer of such delay or cancellation. This may also apply for any other direct or indirect consequential loss that may be borne by the Seller, following this decision.

7.2 In the event of breach by one Party under these conditions or the order, the non-breaching Party may send a notification to the other by recorded delivery letter upon which, after a period of thirty (30) days without solving the problem, the non-breaching Party shall be entitled to terminate all the pending orders, without being liable for any compensation.

8. MISCELLANEOUS

All the provisions of these Terms and Conditions are for the benefit of the Seller itself, but also for its licensors, employees and agents. Each of them is entitled to assert and enforce those provisions against the Buyer.

Any notices under these Terms and Conditions shall be given in writing. They shall be effective upon receipt by the other Party.

The Seller may, from time to time, update these Terms and Conditions and the Buyer, is deemed to have accepted the latest version of these terms and conditions, provided they have been communicated to him in due time.

9. GOVERNING LAW AND JURISDICTION

9.1 Any dispute arising out or linked to these Terms and Conditions or to any contract (orders) entered into in application of these Terms and Conditions shall be settled by the French Commercial Courts of Grasse, which shall have exclusive jurisdiction upon such issues.

9.2 French law shall govern the relation between the Buyer and the Seller, in accordance with these Terms and Conditions.




KNOWMADE

Company presentation

CUSTOM STUDY & CONSULTING

Tailor-made analysis to meet your needs and budgetary constraints

**Knowmade services are at the border between IP and Innovation.
Tailor made analyses allow you to define the scope and focus to fit in your needs and budget.**



KNOWMADE ACTIVITIES

Our main fields of expertise

RF & Telecommunication

- Emerging materials
- Compound semiconductor
- RF filters & Amplifiers
- Front end modules
- Antenna

Medtech & Agrifood

- Microfluidic
- Medical diagnostic
- Biotech & Pharmaceuticals
- Agrifood



MEMS, Sensors & Display

- Optical sensors
- MEMS transducers and sensors
- Optical sources & display

Power

- Emerging materials
- Compound semiconductor
- Battery & power managements
- Power electronics



www.knowmade.com

contact@knowmade.fr

KnowMade S.A.R.L., 2405 route des Dolines, 06902 Sophia Antipolis, France